

# Stanford

---

## Chandni Patel

Postdoctoral Scholar, Biochemistry

### Bio

---

#### PROFESSIONAL EDUCATION

- Doctor of Philosophy, Stanford University , BIOC-PHD (2024)
- B.S., University of California, San Diego , Biochemistry and Cell Biology (2016)

#### STANFORD ADVISORS

- Rajat Rohatgi, Postdoctoral Faculty Sponsor

### Publications

---

#### PUBLICATIONS

- **Gene-teratogen interactions influence the penetrance of birth defects by altering Hedgehog signaling strength.** *Development (Cambridge, England)*  
Kong, J. H., Young, C. B., Pusapati, G. V., Espinoza, F. H., Patel, C. B., Beckert, F., Ho, S., Patel, B. B., Gabriel, G. C., Aravind, L., Bazan, J. F., Gunn, T. M., Lo, et al  
2021
- **A Membrane-Tethered Ubiquitination Pathway Regulates Hedgehog Signaling and Heart Development.** *Developmental cell*  
Kong, J. H., Young, C. B., Pusapati, G. V., Patel, C. B., Ho, S. n., Krishnan, A. n., Lin, J. I., Devine, W. n., Moreau de Bellaing, A. n., Athni, T. S., Aravind, L. n., Gunn, T. M., Lo, et al  
2020
- **Haploinsufficiency networks identify targetable patterns of allelic deficiency in low mutation ovarian cancer.** *Nature communications*  
Delaney, J. R., Patel, C. B., Willis, K. M., Haghghiabyaneh, M., Axelrod, J., Tancioni, I., Lu, D., Bapat, J., Young, S., Cadassou, O., Bartakova, A., Sheth, P., Haft, et al  
2017; 8: 14423-?
- **Nelfinavir is effective against human cervical cancer cells *in vivo*: a potential treatment modality in resource-limited settings.** *Drug design, development and therapy*  
Davis, M. A., Delaney, J. R., Patel, C. B., Storgard, R., Stupack, D. G.  
2016; 10: 1837-46
- **A strategy to combine pathway-targeted low toxicity drugs in ovarian cancer** *ONCOTARGET*  
Delaney, J. R., Patel, C., McCabe, K. E., Lu, D., Davis, M., Tancioni, I., von Schalscha, T., Bartakova, A., Haft, C., Schlaepfer, D. D., Stupack, D. G.  
2015; 6 (31): 31104-31118